Syreeta Tilghman to Cost-Benefit Analysis
This is a "connection" page, showing publications Syreeta Tilghman has written about Cost-Benefit Analysis.
Connection Strength
0.171
-
Gupta A, Gupta G, Mehta RR, Ivancic DZ, Walker RR, Patel JR, Gallegos KM, Davidson AM, Khan SA, Mehta RG, Tilghman SL. A novel and cost-effective ex vivo orthotopic model for the study of human breast cancer in mouse mammary gland organ culture. Biol Open. 2020 05 29; 9(5).
Score: 0.171